Evidence map›Paper›PMID 21695154›Full record

ArticlePloS one2011

BMP9 protects septal neurons from axotomy-evoked loss of cholinergic phenotype.

Ignacio Lopez-Coviella, Tiffany J Mellott, Aletta C Schnitzler, Jan K Blusztajn

Abstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Peptides Derived from Growth Factors to Treat Alzheimer's Disease.International journal of molecular sciences · 2021
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer's disease.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
  8. BMP signaling in mesenchymal stem cell differentiation and bone formation.Journal of biomedical science and engineering · 2013
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ignacio Lopez-CoviellaDepartment of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Tiffany J Mellott
Aletta C Schnitzler
Jan K Blusztajn

Funding

TIME FRAMES OF CHOLINE ENHANCEMENT OF MEMORYP01AG009525 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BLUSZTAJN, JAN KRZYSZTOF · 1991 to 2010
$11.8M
Juvenile trophic factors for the prevention and treatment of hippocampal agingR01AG032709 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BLUSZTAJN, JAN KRZYSZTOF · 2008 to 2010
$1.1M
NIA NIH HHS AG009525NIA NIH HHS AG032709NIA NIH HHS P01 AG009525NIA NIH HHS R01 AG032709
6 · The paper itself

Abstract

backgroundCholinergic projection from the septum to the hippocampus is crucial for normal cognitive function and degeneration of cells and nerve fibers within the septohippocampal pathway contributes to the pathophysiology of Alzheimer's disease. Bone morphogenetic protein (BMP) 9 is a cholinergic differentiating factor during development both in vivo and in vitro. METHODOLOGY/PRINCIPAL

findingsTo determine whether BMP9 could protect the adult cholinergic septohippocampal pathway from axotomy-evoked loss of the cholinergic phenotype, we performed unilateral fimbria-fornix transection in mice and treated them with a continuous intracerebroventricular infusion of BMP9 for six days. The number of choline acetyltransferase (CHAT)-positive cells was reduced by 50% in the medial septal nucleus ipsilateral to the lesion as compared to the intact, contralateral side, and BMP9 infusion prevented this loss in a dose-dependent manner. Moreover, BMP9 prevented most of the decline of hippocampal acetylcholine levels ipsilateral to the lesion, and markedly increased CHAT, choline transporter CHT, NGF receptors p75 (NGFR-p75) and TrkA (NTRK1), and NGF protein content in both the lesioned and unlesioned hippocampi. In addition, BMP9 infusion reduced bilaterally hippocampal levels of basic FGF (FGF2) protein. CONCLUSIONS/SIGNIFICANCE: These data indicate that BMP9 administration can prevent lesion-evoked impairment of the cholinergic septohippocampal neurons in adult mice and, by inducing NGF, establishes a trophic environment for these cells.

Indexed as

PhenotypeAcetylcholineAnimalsAxotomyBiomarkersCholine O-AcetyltransferaseFornix, BrainGene Expression Regulation, EnzymologicGrowth Differentiation Factor 2Growth Differentiation FactorsHippocampusHumansInfusion PumpsMaleMiceNerve Growth FactorAcetylcholineBiomarkersCholine O-AcetyltransferaseGDF2 protein, humanGrowth Differentiation Factor 2Growth Differentiation FactorsNerve Growth FactorReceptor, Nerve Growth FactorReceptor, trkA

Identifiers

PMID21695154
PMCPMC3113905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.